Kornimate/medical-research-clean huggingface dataset:
photobiomodulation in head and neck cancer-related chronic lymphedema

Conditions: Head and Neck Cancer; Lymphedema of the Head and Neck

Summary: the u.s. food and drug administration approved photobiomodulation therapy (pbmt) as a treatment for breast cancer-related arm lymphedema (bcrl) in 2006. the investigators conducted two pilot clinical trials. results demonstrated the feasibility, acceptability, and preliminary efficacy of pbmt for the treatment of chronic lymphedema in head and neck cancer (hnc) survivors. the objective of this study is to further investigate and confirm the positive effects of pbmt on hnc-related chronic lymphedema.


Eligibility criteria:
inclusion criteria: \>18 years of age biopsy proven head and neck cancer no evidence of cancer at the time of study enrollment, between 12- and 60-month post-cancer treatment chronic lymphedema (defined as lymphedema persisting for a minimum of 6 months) a minimum of 2 sites of external lymphedema at least 1 site with lymphedema of moderate severity as assessed using the hn-lef assessment criteria failed lymphedema therapy (defined as any of the following: incomplete response to therapy, progression of lymphedema after therapy, inability to perform effective self-care resulting in fluid re-accumulation; and inability to complete treatment due to systems barriers). in addition, patients must be able to understand english in order to complete questionnaires; and to provide informed consent. exclusion criteria: patients will be excluded if they have any of the following medical conditions that would prohibit the safe implementation of pbmt: women of childbearing age and potential acute cellulitis within the soft tissues in the head and neck region chronic inflammatory diseases venous thrombosis carotid artery stenosis requiring ongoing use of diuretics and corticosteroids pre-existing skin rash, ulceration, open wound in the treatment area active lymphedema or physical therapy (including hyperbaric oxygen or trental) allergic and other systemic skin diseases

Keywords: head and neck cancer, chronic lymphedema, photobiomodulation
non-invasive lipolysis and improvement of muscle tone in lateral abdomen

Conditions: Fat Burn

Summary: this study will evaluate the clinical efficacy and performance of the btl-899 device for changes in subcutaneous fat and muscle tissue in the lateral abdomen region (also referred to as flanks or "love handles"). the study is a prospective, multi-center, open-label, single-arm study. the subjects will be enrolled and assigned into a single study group. subjects will be required to complete four (4) treatment visits and two follow-up visits. all of the study subjects will receive the treatment with the subject device.

at the baseline visit, mri imaging will be performed; the subject's weight and waist circumference will be recorded. digital photographs of the treated area will be taken. the treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. the applicators of btl-899 will be applied over the area of flanks. the device will induce visible muscle contractions along with heating of the subcutaneous fat. each therapy session will last 30 minutes. at the last therapy visit, the subject's weight and waist circumference will be recorded, and digital photographs of the treated area will be taken. in addition, subjects will receive therapy comfort and subject satisfaction questionnaire to fill in. safety measures will include documentation of adverse events (ae), which will be assessed after each procedure and at all of the follow-up visits.

Eligibility criteria:
inclusion criteria: * age 22 years and older * voluntarily signed an informed consent form * bmi ≤ 35 kg/m2 * women of child-bearing potential are required to use birth control measures during the whole duration of the study * subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring during study participation * subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation exclusion criteria: * electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators) * metal implants * drug pumps * malignant tumor * pulmonary insufficiency * injured or otherwise impaired muscles * cardiovascular diseases * disturbance of temperature or pain perception * hemorrhagic conditions * septic conditions and empyema * acute inflammations * systemic or local infection such as osteomyelitis and tuberculosis * contagious skin disease * elevated body temperature * pregnancy, postpartum period, nursing, and menstruation * a metal-containing intrauterine device (iud) * swollen or neoplastic tissues, space-occupying lesions or skin eruptions in the treatment area * graves' disease

Keywords: muscle toning fat reduction
trigeminal brainstem mapping 2: higher cortical strucureas as well as subnuclei of the spinal trigeminal nucleus

Conditions: Migraine Disorders

Summary: in previous studies clustering of the three branches of the trigeminal nerve in brainstem were shown, cerebellum and periaqueductal gray. to further evaluate higher cortical structures, which were not covered by our previous field of view (fov) and to further investigate the identified 'subnuclei' of the spinal trigeminal nucleus, here the aim is to scan the whole brain as well as the brainstem and the upper spinal cord during trigeminal nociceptive as well as non-nociceptive electrical stimulation of all three branches of the trigeminal nerve (and the arm as a somatic control site) during acquisition of bold-fmri in humans.

preprocessing and processing of the mr data will follow our previous publications (mehnert et al 2023, mehnert et al 2024)

Eligibility criteria:
inclusion criteria: * healthy * suitable fo mri exclusion criteria: * headache disease * psychological disorder * pregnancy * all exclusion criteria necessary for imaging in a 3 t mri scanner
comparing hypo-fractionated intensity- modulated radiation therapy to standard- fractionated imrt along with chemotherapy and immunotherapy for non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer Stage

Summary: the hypothesis for this study is that hypofractionated imrt to 62.5 gy in 25 fractions (2.5 gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18 months by 10% compared to standard-fractionated chemo-imrt/durvalumab. a modest improvement in locoregional control (lrc) was selected as a target which could merit further study of this hypofractionated imrt regimen in a phase iii trial


Eligibility criteria:
inclusion criteria: * ability of participant or legally authorized representative (lar) to understand this study, and participant or lar willingness to sign a written informed consent * males and females age ≥ 18 years * eastern cooperative oncology group (ecog) performance status 0 - 2 * measurable disease by recist 1.1 * women of childbearing potential must have a negative serum pregnancy test within one month prior to initiating treatment * pathologically proven diagnosis of stage iiia or iiib non-small cell lung cancer (nsclc) * no positron emission tomography (pet)/ct evidence of metastatic disease * an mri of the brain with contrast excluding intracranial metastatic disease (or ct with contrast if mri is medically contraindicated). an mri without contrast is only permitted if the subject cannot have contrast for medical reasons * if a pleural effusion is present, it must be tapped and confirmed to be cytologically negative. if an effusion is deemed too small to safely tap, the subject will be eligible * women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in child-bearing potential/pregnancy section for the duration of study participation and for 90 days following completion of therapy * adequate organ function per laboratory results exclusion criteria: * current or anticipating use of other anti-neoplastic or investigational agents while participating in this study * diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements * evidence of severe or systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) that would interfere with study protocol as judged by the investigator * is pregnant or breastfeeding * active connective tissue disorders, such as active lupus or scleroderma * known acquired immune deficiency (hiv (+)/aids) * has a known allergic reaction to any excipient contained in the study drug formulations * active grade 3 (per the nci ctcae, version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment * prior thoracic radiotherapy
intranasal ketamine effectiveness in reducing intramuscular injection pain before sedation among children

Conditions: Pain; Intranasal Ketamine

Summary: hypothesis: intranasal administration of ketamine would reduce the intramuscular pain of ketamine injection in children who undergo procedural sedation and analgesia in the emergency department.

ketamine is a well-known medication in children's procedural sedation and analgesia. while it provides good analgesia along with sedation, its injection is painful and causes distress in children. intranasal administration of ketamine would reduce the intramuscular pain of ketamine injection in children who undergo procedural sedation and analgesia in the emergency department. this will also assess if intranasal administration would affect the depth of sedation and hospital length of stay of this group of patients.

Eligibility criteria:
inclusion criteria: • children who need to undergo procedural sedation and analgesia exclusion criteria: * weight over 33 kg * no consent from parents/patient * needs immediate procedure due to patient's condition * growth/mental retardation * sensory deficit at the site of intramuscular injection
"concentrated exposure treatment" (cet) for for obsessive compulsive disorder

Conditions: Obsessive Compulsive Disorder (OCD)

Summary: obsessive compulsive disorder (ocd) often becomes chronic if not treated. exposure and response prevention (erp) is recommended psychological treatment. the ocd-team at haukeland university hospital has developed a concentrated 4-day treatment format which has been evaluated as part of standard care. next step in the methodological development is to conduct a randomized controlled trial where the 4-day format is compared to self-help and waiting list. the study will be conducted at solvang dps, sørlandet hospital. participants (16 in each group) are ordinary patients (\>18 yrs) entitled to care in the specialist health care.


Eligibility criteria:
inclusion criteria: ocd-patients referred to the ocd-team at sørlandet sykehus, solvang dps will be included. inclusion criteria * outpatients * ≥ 18 years of age * fulfilling diagnostic criteria of ocd according to the dsm-5 * y-bocs ≥ 16 * fluent in norwegian * signed informed consent exclusion criteria: * ocd symptoms primarily associated with hoarding * ongoing substance abuse/dependence * bipolar disorder or psychosis * ongoing suicidal ideation * mental retardation, based on previous medical history * if using antidepressants: * not on stable dosage 4 weeks before the intervention * unwilling to remain on stable dosage during the four intervention days * unwilling to refrain from anxiety reducing substances, such as anxiolytics (e.g. benzodiazepines) and alcohol during the two days of exposure. * patients living \> 1.5 hour drive by car/ train from the treatment location. * patients with a bmi-index considered too low for participation in psychological treatment * patients with a full course of prior cbt for ocd.
non-invasive ventilation preoperative lung resection surgery

Conditions: Surgery for Primary Lung Cancer

Summary: surgical treatment is the standard treatment for localized forms of lung cancer non-small cell. it allows a 5-year survival exceeding 50% for complete resection of the tumor. this is a heavy treatment, resulting in a mortality of 4 to 8% and a morbidity of 20-60%. securing this procedure is a major public health issue. the non-invasive ventilation is a technique commonly used postoperatively in acute respiratory distress and in the treatment of sleep apnea syndromes. through its effect on oxygenation and pulmonary function parameters, the non-invasive ventilation achieved during 7 days minimum before the intervention could significantly reduce postoperative complications in patients with an obstructive or restrictive disorder, obesity or chronic heart failure. the aim of the study is to demonstrate that the non-invasive ventilation in two pressure levels achieved during at least 7 days before surgery lung resection (lobectomy or segmentectomy) halved the pulmonary and cardiovascular postoperative patients with obstructive ventilatory disorder or restrictive, obesity or chronic heart failure.


Eligibility criteria:
inclusion criteria: * patient over 18 years, to benefit from surgery scheduled for lung resection (lobectomy or segmentectomy) for primary lung cancer and having signed an informed consent. and * trouble obstructive (fev / fvc \<70% and fev \<80% predicted) or restrictive (fvc \<80% or tlc \<80%) or decrease in the ratio tlco / va \<60% or history of respiratory failure with hypercapnic pa co2\> 45 mmhg in the year preceding surgery or long-term oxygen or heart failure (clinical signs of heart failure and lvef \<55% or disorder of relaxation on echocardiography or atrial fibrillation) or history of acute cardiogenic pulmonary edema. or obesity (bmi\> 30 kg/m2) exclusion criteria: * inability to consent * patient declared inoperable given the comorbidities or refusing surgery or with unresectable tumors. * patient operable but with no comorbidities described in the inclusion criteria * contraindications to the non-invasive ventilation: * lack of understanding of the technical * facial malformation * tight stenosis of the upper airway * uncontrollable vomiting * unable to remove the mask * cognitive impairment or severe psychiatric jeopardizing the observance of the nav * patient non-insured * patient already on invasive ventilation or non-invasive * during pregnancy

Keywords: primary lung cancer lobectomy pneumonectomy non-invasive ventilation
intergroup randomized trial for children or adolescents with b-cell non hodgkin lymphoma or b-acute leukemia: rituximab evaluation in high risk patients

Conditions: B-cell Non Hodgkin Lymphoma; Mature B-cell Leukemia Burkitt-type

Summary: the aim of the trial is to test whether adding 6 injections of rituximab to standard "lymphome malin b" lmb chemotherapy regimen improves the event free survival (efs) compared with lmb chemotherapy alone in children / adolescents with advanced stage b-cell non-hodgkin lymphoma (nhl) / b-acute leukemia (b-al)(stage iii and ldh \> nx2, any stage iv or b-al).


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven b-cell malignancies, either burkitt lymphoma or b-al (=burkitt leukaemia = l3-al) or diffuse large b-cell nhl or aggressive mature b-cell nhl non other specified or specifiable. * stage iii with elevated ldh level ("b-high"), \[ldh \> twice the institutional upper limit of the adult normal values (\> nx2)\] or any stage iv or b-al. * 6 months to less than 18 years of age at the time of consent. * males and females of reproductive potential must agree to use an effective contraceptive method during the treatment, and after the end of treatment: during twelve months for women, taking into account the characteristics of rituximab and during five months for men, taking into account the characteristics of methotrexate. * complete initial work-up within 8 days prior to treatment that allows definite staging. * able to comply with scheduled follow-up and with management of toxicity. * signed informed consent from patients and/or their parents or legal guardians exclusion criteria: * follicular lymphoma, malt and nodular marginal zone are not included into this therapeutic study * patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive hiv serology. * evidence of pregnancy or lactation period. * there will be no exclusion criteria based on organ function. * past or current anti-cancer treatment except corticosteroids during less than one week. * tumor cell negative for cd20 * prior exposure to rituximab. * severe active viral infection, especially hepatitis b. * hepatitis b carrier status history of hbv or positive serology. * participation in another investigational drug clinical trial. * patients who, for any reason, are not able to comply with the national legislation.
biomarkers in predicting response in patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy

Conditions: Lung Cancer

Summary: this research trial studies prognostic and predictive markers in patients with early stage non-small cell lung cancer receiving chemotherapy. prognostic markers are patient or tumor factors that predict patient survival independent of treatment. predictive markers are factors that may influence and predict the outcome of treatment in terms of either response or survival benefit. collecting and storing samples of tissue from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer.

primary objectives: i. evaluate potential prognostic and predictive markers in patients receiving adjuvant chemotherapy for early stage non-small cell lung cancer (nsclc). ii. to perform cross-validation analyses for the predictive value of cyclin-dependent kinase inhibitor 1b (p27), excision repair cross-complementation group 1 (ercc1), beta-tubulin and b-cell lymphoma 2 (bcl2)-associated x protein (bax). iii. to perform cross-validation analyses for the prognostic value of mucin and breast cancer (brca)1 expression. iv. to perform a pooled analysis for the prognostic impact of p53 protein expression by immunohistochemistry (ihc), tumor protein p53 (p53) mutation, ras mutation and epidermal growth factor receptor (egfr) mutation, and fas cell surface death receptor (fas)/fas ligand (fasl) expression by ihc. v. validation of the 15-gene prognostic and predictive messenger ribonucleic acid (mrna) signature on lung adjuvant cisplatin evaluation (lace)-bio formalin-fixed paraffin-embedded (ffpe) tumor samples. vi. exploratory evaluation of the prognostic and predictive values of known potential oncogenic mutations using lace-bio ffpe. vii. exploratory evaluation of the prognostic and predictive values of gene copy variation using lace-bio ffpe tumor samples. viii. exploratory identification and evaluation of prognostic and predictive value of novel genomic aberrations discovered by next generation sequencing on lace-bio tumor samples. outline: previously collected tissue samples are analyzed by ihc.

Eligibility criteria:
inclusion criteria: * registration to calgb9633 for this study * institutional review board (irb) review and approval at the institution where the laboratory work will be performed is required * informed consent: * the subject population to be studied in this protocol includes patients selected from calgb 9633 for whom an available specimen is present at the alliance ohio state university (osu); all such patients have signed a written informed consent document meeting all federal, state, and institutional guidelines as part of entry into that trial * only cases with adequate tumor formalin ffpe material without depleting the available clinical block(s) are eligible

Keywords: stage i non-small cell lung cancer stage ii non-small cell lung cancer
itch and clinacal caracteristics in systemic sclerosis

Conditions: Pruritus; Systemic Sclerosis

Summary: systemic sclerosis (ssc) has heterogeneous symptoms and significant medical morbidity. recently, itch was described as a symptom of ssc (prevalence of 42,6%). to the investigators knowledge, no study yet has examined the clinical features of itch neither had used a specific itch-related quality of life (qol) scales in patients with ssc. the objectives were to evaluate the prevalence of pruritus, its characteristics and its impact on the qol in those patients. in this descriptive study, patients followed for ssc in the departments of dermatology, rheumatology, internal medicine and pulmonology at the university hospital of brest were included. participants received a questionnaire including questions about the clinical features of pruritus and 2 scores (5-d itch scale, itchyqol).


Eligibility criteria:
inclusion criteria: * aged more than 18 years * followed for systemic sclerosis since 2000, in the departments of dermatology, rheumatology, internal médicine or pneumology at the university hospital of brest. exclusion criteria: * lower than 18 years * refusal to participate
influence of kidney performance and magnesium on formation of (oh)2-vitamin d3

Conditions: Hydroxylase Deficiency

Summary: retrospective database analysis. the target values are the serum values of 25(oh)d, of 1,25(oh)2d, of magnesium and creatinine as well as age and sex of the patients. the laboratory values of the years 2017 and 2018 are included. there are no additional measurements on patients.

the laboratory values of the years 2017 and 2018 are included. all laboratory results to be evaluated originate from medics labor in bern. we expect about 50'000 data sets. it is impossible for the study team to draw conclusions about the patients or the senders.

Eligibility criteria:
inclusion criteria: * all data sets available exclusion criteria: * a declaration from the patient that his laboratory values may not be included in an evaluation.

Keywords: vitamin d 1-alpha hydroxylase magnesium renal insufficiency